BioCentury
ARTICLE | Financial News

Actelion reports 17% sales increase in first half

July 23, 2014 12:45 AM UTC

Actelion Ltd. (SIX:ATLN) reported total sales of CHF993 million ($1.1 billion) in the first half, a 17% increase compared to the same year-ago period. Core EPS rose by 48% in constant currency to CHF3.25. Actelion attributed growth largely to increasing sales of pulmonary arterial hypertension drug Opsumit macitentan, which Actelion launched in the U.S. six months ago and is now covered by most leading insurance companies and formularies in the U.S. The company started marketing the tissue-targeting endothelin receptor antagonist in 10 countries in 1H14 and plans to market the drug in Australia, Italy, France and Spain by the end of 2015. The company also disclosed that it submitted a regulatory filing in Japan in the first half.

Actelion said it will look for acquisitions outside the PAH space to continue its growth trajectory. The company said it now expects full-year core EPS growth to be in the mid-teens, up from its previous guidance of the upper single digits. ...